[go: up one dir, main page]

JP2006527741A5 - - Google Patents

Download PDF

Info

Publication number
JP2006527741A5
JP2006527741A5 JP2006516231A JP2006516231A JP2006527741A5 JP 2006527741 A5 JP2006527741 A5 JP 2006527741A5 JP 2006516231 A JP2006516231 A JP 2006516231A JP 2006516231 A JP2006516231 A JP 2006516231A JP 2006527741 A5 JP2006527741 A5 JP 2006527741A5
Authority
JP
Japan
Prior art keywords
hfddde
hexapeptide
active ingredient
preventing
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006516231A
Other languages
Japanese (ja)
Other versions
JP2006527741A (en
Filing date
Publication date
Priority claimed from FI20030923A external-priority patent/FI20030923A7/en
Priority claimed from FI20040616A external-priority patent/FI20040616A0/en
Application filed filed Critical
Priority claimed from PCT/FI2004/000376 external-priority patent/WO2004110478A1/en
Publication of JP2006527741A publication Critical patent/JP2006527741A/en
Publication of JP2006527741A5 publication Critical patent/JP2006527741A5/ja
Withdrawn legal-status Critical Current

Links

Claims (4)

ヘキサペプチド ＨＦＤＤＤＥを有効成分として含有する医薬。   A pharmaceutical containing hexapeptide HFDDDE as an active ingredient. ヘキサペプチド ＨＦＤＤＤＥを有効成分として含有する、炎症性病態の予防または治療のための医薬。   A pharmaceutical agent for preventing or treating inflammatory pathology, comprising hexapeptide HFDDDE as an active ingredient. 有効成分としてのヘキサペプチド ＨＦＤＤＤＥと少なくとも１種の薬学的に許容される担体とを含んでなる医薬組成物。   A pharmaceutical composition comprising hexapeptide HFDDDE as an active ingredient and at least one pharmaceutically acceptable carrier. ヘキサペプチド ＨＦＤＤＤＥを有効成分として含有する、炎症性病態の予防用または治療用医薬組成物。   A pharmaceutical composition for preventing or treating an inflammatory disease state, comprising the hexapeptide HFDDDE as an active ingredient.
JP2006516231A 2003-06-19 2004-06-21 Inhibitors of cell migration Withdrawn JP2006527741A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030923A FI20030923A7 (en) 2003-06-19 2003-06-19 Leukocyte proMMP-9/beta2 integrin complex inhibitors
FI20040616A FI20040616A0 (en) 2004-04-29 2004-04-29 Cellmigrationsinhibitorer
PCT/FI2004/000376 WO2004110478A1 (en) 2003-06-19 2004-06-21 Inhibitors of cell migration

Publications (2)

Publication Number Publication Date
JP2006527741A JP2006527741A (en) 2006-12-07
JP2006527741A5 true JP2006527741A5 (en) 2007-08-02

Family

ID=33553915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006516230A Withdrawn JP2006527740A (en) 2003-06-19 2004-06-21 Inhibitors of proMMP-9 / β2 integrin complex in leukocytes
JP2006516231A Withdrawn JP2006527741A (en) 2003-06-19 2004-06-21 Inhibitors of cell migration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006516230A Withdrawn JP2006527740A (en) 2003-06-19 2004-06-21 Inhibitors of proMMP-9 / β2 integrin complex in leukocytes

Country Status (3)

Country Link
EP (2) EP1644032A1 (en)
JP (2) JP2006527740A (en)
WO (2) WO2004110478A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006208969A1 (en) * 2005-01-31 2006-08-03 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic peptides derived from urokinase plasminogen activator receptor
GB2429012A (en) * 2005-08-12 2007-02-14 Cartela Ab Polypeptides capable of binding an integrin I-domain.
EP1924595A2 (en) * 2005-08-12 2008-05-28 Cartela R & D AB Novel peptides and uses thereof
ES2641751T3 (en) * 2008-11-04 2017-11-13 Index Pharmaceuticals Ab Compounds and methods to reduce the recruitment and / or migration of polymorphonuclear cells
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
EP3600377A4 (en) 2017-03-22 2021-01-06 Children's Medical Center Corporation PRSS2 ESCAPE
WO2018175749A2 (en) 2017-03-22 2018-09-27 Children's Medical Center Corporation Lrp1 binding agents and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US20030022835A1 (en) * 1998-04-29 2003-01-30 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
GB9809764D0 (en) * 1998-05-07 1998-07-08 Isis Innovation MMP-9 Gene polymorphisms
CA2379373A1 (en) * 1999-07-13 2001-01-18 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins
AU4347701A (en) * 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7034134B2 (en) * 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
AU2002364707A1 (en) * 2002-04-23 2003-11-10 Duke University Atherosclerotic phenotype determinative genes and methods for using the same

Similar Documents

Publication Publication Date Title
NO2025027I1 (en) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - extended.
DK1183014T3 (en) Flavored controlled release oral pharmaceutical compositions
NO2017047I1 (en) Tofacitinib, optionally in the form of a pharmaceutically acceptable salt, including citrate salt
JP2004210767A5 (en)
JP2002532112A5 (en)
WO2008011169A3 (en) Controlled release formulations and associated methods
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
WO2006035418A3 (en) Microcapsules comprising a methylxanthine and a corticosteroid
DE50313653D1 (en) WATER-SOLUBLE IRON-CARBOHYDRATE COMPLEXES, THEIR PREPARATION AND THE MEDICAMENTS CONTAINING THEREOF
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
JP2002511411A5 (en)
PT1827396T (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
CL2004000416A1 (en) NITROGEN HETEROCICLIC COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND TO TREAT OR PREVENT A CONDITION THROUGH P38, WHICH CONSISTS OF AN INFLAMMATORY, AUTO-IMMUNE, VIROSICAL OR NEURODEGENERATIVE DISEASE.
JP2007523135A5 (en)
EA200901393A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENES AND / OR ESTROGENS AND 5 METHYL- (6S) -TETRAHYDROPHOLATE
ITMI20022292A1 (en) 9A-AZALIDS WITH ANTI-INFLAMMATORY ACTIVITY.
JP2005509503A5 (en)
NL1028193A1 (en) Pharmaceutically active compounds.
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
DE60102590D1 (en) PHARMACEUTICAL FORMS FOR TREATING ORAL MYCOSIS
ITMI20021725A1 (en) PHARMACEUTICAL COMPOSITIONS WITH ANTIBIOTIC ACTIVITY.
JP2006527741A5 (en)
IL181216A0 (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same
IS8430A (en) Medicines containing (2R) -2-propyl octanoic acid as the active ingredient
WO2004096125A3 (en) Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem